Want to see JP:2929 full AI Analyst Report?
2929 Stock Chart & Stats
¥618.00
¥10.00(1.75%)
At close: 4:00 PM EDT
¥618.00
¥10.00(1.75%)
Day’s Range― - ―
52-Week Range¥513.00 - ¥1,064.00
Previous CloseN/A
Volume102.50K
Average Volume (3M)133.34K
Market Cap
¥17.67B
Enterprise Value¥27.06K
Total Cash (Recent Filing)¥8.77B
Total Debt (Recent Filing)¥17.21B
Price to Earnings (P/E)41.4
Beta0.80
Next Earnings
Sep 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.1%
Share Statistics
EPS (TTM)14.72
Shares Outstanding29,079,000
10 Day Avg. Volume103,440
30 Day Avg. Volume133,336
Financial Highlights & Ratios
PEG Ratio-0.78
Price to Book (P/B)2.21
Price to Sales (P/S)0.39
P/FCF Ratio-12.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)56.8
Revenue Forecast (FY)¥70.00B
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthContinued revenue growth indicates ongoing demand for the company’s branded supplements and functional foods. Sustained sales expansion can support operating scale and provide a foundation for recovery if profitability and cash conversion improve.
Strong Gross MarginAn over-80% gross margin suggests the branded product portfolio retains meaningful value above product costs. This provides potential operating leverage and gives management room to absorb investments or improve earnings if overhead pressures stabilize.
Reduced Financial LeverageLower leverage creates a more balanced capital structure and can reduce financial risk over the medium term. Stable equity support also provides greater flexibility to fund operations, although the benefit depends on restoring profitability and cash generation.
Bears Say
Sharp Profitability DeclineThe steep margin contraction shows that revenue growth is not translating into earnings. If higher operating costs or weaker pricing power persist, the company may have less capacity to reinvest, support dividends, or withstand competitive pressure.
Negative Operating Cash FlowNegative operating cash flow weakens the quality of reported earnings and may force reliance on working-capital changes or external funding. Persistent cash shortfalls could constrain product development, marketing, and the company’s ability to support growth internally.
Deteriorating Returns And Operating MarginsFalling ROE and lower EBIT and EBITDA margins indicate that the business is using its capital less effectively and retaining less operating profit from sales. This points to broader execution or cost pressures beyond the decline in net margin.
Pharma Foods International Co., Ltd. News
2929 FAQ
What was Pharma Foods International Co., Ltd.’s price range in the past 12 months?
Pharma Foods International Co., Ltd. lowest stock price was ¥513.00 and its highest was ¥1064.00 in the past 12 months.
What is Pharma Foods International Co., Ltd.’s market cap?
Pharma Foods International Co., Ltd.’s market cap is ¥17.67B.
When is Pharma Foods International Co., Ltd.’s upcoming earnings report date?
Pharma Foods International Co., Ltd.’s upcoming earnings report date is Sep 11, 2026 which is in 3 days.
How were Pharma Foods International Co., Ltd.’s earnings last quarter?
Pharma Foods International Co., Ltd. released its earnings results on Jun 10, 2026. The company reported ¥26.42 earnings per share for the quarter.
Is Pharma Foods International Co., Ltd. overvalued?
According to Wall Street analysts Pharma Foods International Co., Ltd.’s price is currently Overvalued.
Does Pharma Foods International Co., Ltd. pay dividends?
Pharma Foods International Co., Ltd. pays a Semiannually dividend of ¥12.5 which represents an annual dividend yield of 4.1%. See more information on Pharma Foods International Co., Ltd. dividends here
What is Pharma Foods International Co., Ltd.’s EPS estimate?
Pharma Foods International Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharma Foods International Co., Ltd. have?
Pharma Foods International Co., Ltd. has 29,079,000 shares outstanding.
What happened to Pharma Foods International Co., Ltd.’s price movement after its last earnings report?
Pharma Foods International Co., Ltd. reported an EPS of ¥26.42 in its last earnings report. Following the earnings report the stock price went down -13.376%.
Which hedge fund is a major shareholder of Pharma Foods International Co., Ltd.?
Currently, no hedge funds are holding shares in JP:2929
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pharma Foods International Co., Ltd.
Pharma Foods International Co., Ltd. is a Japanese enterprise dedicated to the research, development, and commercialization of ingredients for functional foods. Its diverse product portfolio features items such as Pharma-GABA, Bonepep, Ovopron (a specific egg yolk globulin), Delicious Catechin, RunPep, and enriched Folic Acid Egg. Additionally, the company offers iHA, a compound recognized for stimulating the body's hyaluronic acid production. Furthermore, Pharma Foods International Co., Ltd. has entered into a licensing arrangement with Mitsubishi Tanabe Pharma Corporation for a novel therapeutic antibody designed to combat autoimmune conditions. The firm was founded in 1997 and maintains its corporate headquarters in Kyoto, Japan.
Technical Analysis
―
Tsumura & Co
―
Wakamoto Pharmaceutical Co., Ltd.
―
Morishita Jintan Co., Ltd.
―
Nippon Chemiphar Co., Ltd.
―